eATP-dependent P2X7R stimulation, followed by the release of IL-1β through the activation of NLRP3 inflammatory bodies, stimulates the activation of DCs and presents antigens to CD4+ and CD8+T lymphocytes, promoting anti-tumor immune response 126. The gene discussed is CD8A; the disease is neoplasm.